Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

UK targets hepatitis C detection:

This article was originally published in Clinica

Executive Summary

A hepatitis C public health campaign has been launched in England, with the main aim of encouraging testing to help detect the more than 100,000 cases thought to remain undiagnosed. The "FaCe It" campaign will run for two years and will be aimed particularly at those people who are, or have been, at higher risk of contracting the hepatitis C virus (HCV), in order to advise them about getting tested. There are approximately 200,000 people chronically infected from HCV, yet the majority of these are unaware of their infection, says the Department of Health. The value of testing for this chronic disease is that it is largely asymptomatic and can develop into potentially serious conditions, yet is responsive to treatment in about 55% of cases.

You may also be interested in...



Human Cell-Secreted Proteins Offer A Wellspring Of Potential Therapeutics

CEO Hanadie Yousef leads Juvena Therapeutics in utilizing an AI-based platform that analyzes cell-secreted proteins to identify potential therapeutics. One of their first near-clinical assets could complement GLP-1s.

Adalvo Hails First European Launch Of Prolonged-Release Pregabalin

After the drug’s approval for use in neuropathic pain within the EU last December, Adalvo announced the analgesic’s first European launch in Germany.

Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results

Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT060423

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel